ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Dicer and microRNA-155 dysregulation in multiple sclerosis: biomarkers for disease progression and treatment response.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple Sclerosis (MS) is an immunological disorder that progressively leads to neurological dysfunction. Dysregulated microRNA expression, particularly miR-155, has been implicated in MS pathogenesis. Dicer, an enzyme responsible for processing precursor microRNAs into their mature forms, is also dysregulated in various conditions, including MS.
objectivesThis study aimed to assess plasma expression levels of miR-155 and Dicer mRNA in MS patients compared to healthy individuals and evaluate their diagnostic value and clinical significance.
methodsWe analyzed plasma samples from twenty untreated MS patients, 20 MS patients receiving IFNβ1a therapy, and twenty healthy controls. Quantitative real-time PCR was used to quantify miR-155 and Dicer mRNA levels.
resultsMiR-155 was significantly higher in untreated MS patients compared to both healthy controls and IFNβ1a-treated group (p < 0.001). MiR-155 correlated positively with the Expanded Disability Status Scale (EDSS) (r = 0.683, p < 0.001). Conversely, plasma Dicer mRNA levels didn't differ significantly between untreated MS patients and controls. However, Dicer mRNA expression was significantly elevated in the IFNβ1a-treated patients compared to both untreated MS patients (p < 0.001) and healthy controls (p = 0.001).
conclusionsOur findings suggest that miR-155 may serve as a promising biomarker for MS diagnosis and disease severity. While Dicer mRNA expression showed limited diagnostic utility, its upregulation in IFNβ1a-treated patients suggests a potential role in monitoring disease progression and treatment response.
Indexed as
Identifiers
40991083What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.